Skip to main content
Natera, Inc. logo

Natera, Inc. — Investor Relations & Filings

Ticker · NTRA ISIN · US6323071042 LEI · 529900CQ3OZ0A0VYVU59 US Human health and social work activities
Filings indexed 1,585 across all filing types
Latest filing 2020-03-24 Director's Dealing
Country US United States of America
Listing US NTRA

About Natera, Inc.

https://www.natera.com/

Natera, Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) testing. The company develops and commercializes non-invasive tests focused on three primary areas: women's health, oncology, and organ health. In women's health, its products include the Panorama non-invasive prenatal test (NIPT) and the Horizon carrier screening test to assess genetic risks. The oncology portfolio features Signatera, a personalized molecular residual disease (MRD) test used to monitor cancer recurrence and treatment response. For organ health, its tests are designed to detect early signs of transplant rejection. Natera's technology aims to provide actionable information for personalized medical care, supported by extensive clinical validation through numerous peer-reviewed studies.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2020-03-24 English
4 Filing
Director's Dealing
2020-03-24 English
4 Filing
Director's Dealing
2020-03-24 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement between Natera, Inc. and Qiagen LLC, including details about the agreement, breach, and ongoing discussions. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a presentation, earnings release, or management discussion. It is a regulatory announcement about a significant contractual event. Therefore, the appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories. The document length is 4830 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the form and content.
2020-03-12 English
4 Filing
Director's Dealing
2020-03-11 English
4 Filing
Director's Dealing
2020-03-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.